Medrxiv:确诊增加100倍,Omicron亚型BA.2变种和其他新冠变异株流行病学特征比较!

2022-04-22 病毒学 “生命科学前沿”公众号

2022年初,SARS-CoV-2 Omicron BA.2变异株导致香港3个月的时间里出现110多万例确诊病例,是前两年所有四次疫情波中确诊病例的100倍。

2021年11月24日,世界卫生组织(WHO)首次收到南非对于奥秘克戎突变株的报告,并于2日后将其列入值得关注的突变株(Variant of Concern,VOC)。实际上,Omicron亚型BA.2迅速取代了BA.1而成为主要的流行株。中国香港正在经历的Omicron疫情正属于此亚型。

2022年4月7日Medrxiv在线发表了来自香港大学李嘉诚医学院公共卫生学院世界卫生组织传染病流行病学与控制合作中心的研究文章:Epidemiology of infections with SARS-CoV-2 Omicron BA.2 variant in Hong Kong。在这篇文章里,研究人员比较了本次引起香港疫情的Omicron BA.2 变异株与其他SARS-CoV-2变异株的潜伏期、感染时间和传播速度,详细描述了香港本次疫情的流行病学特征。

香港在2020—2021年持续出现四次小流行新冠疫情爆发,累计确诊病例12631例(每1000人口1.6例),累计死亡病例213例 。但是2022年初,SARS-CoV-2 Omicron BA.2变异株导致香港3个月的时间里出现110多万例确诊病例,是前两年所有四次疫情波中确诊病例的100倍。

在疫情爆发的一个多月时间内,通过RTPCR和快速抗原检测发现的每日病例数呈指数增长,其翻倍时间为3.4天,并于2022年3月4日达到峰值。

Omicron BA.2具有很强的传播能力。2022年1月22日香港确诊了136例Omicron感染新冠患者,其中72%(98/136)具有明确的传播链。98例确诊病例中,34%(33例)为Omicron BA.2变异株,55%(54例)为女性患者,73%为已完成初级系列疫苗接种的人群。其中80例(82%)在确诊时明确出现了症状。

接下来,研究人员利用80例患者(57 例BA.1和23例BA.2)的已知的暴露信息和发病信息估计潜伏期。其中Omicron BA.1的平均潜伏期为4.58(±1.72)天,Omicron BA.2的平均潜伏期4.42(±1.42)天。95%的患者感染了Omicron BA.1后7.7天内出现症状,而感染Omicron BA.2的患者95%则在7.0天内出现症状。

最后,研究人员利用43对感染者的数据进行了Omicron变异株的感染时间间隔进行区间估计。BA.1 (n=30)的平均间隔时间为3.30 (±1.95) 天,中位间隔时间为 3.17 天。BA.2 (n=13)的平均间隔时间为 2.72 (±1.51) 天,中位间隔时间为 2.52天。

此外,研究人员还根据疫苗接种状况对香港第1-4波疫情和第5波疫情中的病死率进行了年龄分层估计。结果表明,在第 5 波疫情中未完成疫苗接种病例的年龄特异性病死风险 (CFR) 与第 1-4 波疫情中相近。 在第 1-4 波中观察到 80 岁及以上患者的死亡风险最高(CFR=24.9%),第 5 波疫情同龄未接种疫苗的患者表现出相似的死亡风险(CFR=21.7%)。但是在第 5 波疫情中未完成疫苗接种的 ≥80 岁人群的死亡风险(CFR=24.9%)是已完成主疫苗接种的同一年龄组人群(CFR=11.1%)大约两倍,64-79 岁的确诊病例也有类似的流行病学特征。

总的来说,这项研究表明Omicron 突变株特别是本次香港大流行的 BA.2 突变株显示出非常高的传播潜力。与未接种疫苗或接种疫苗不完整的病例相比,具有完整疫苗接种的病例的死亡风险要低得多。这个研究结果强调了实现高覆盖率疫苗接种的重要性,尤其是在老年人中接种新冠疫苗可以明显降低死亡风险。

原始出处:

Yonatan Mefsin, Dongxuan Chen, Helen S. Bond, et al. Epidemiology of infections with SARS-CoV-2 Omicron BA.2 variant in Hong Kong, January-March 2022. medRxiv 2022.04.07.22273595; doi: https://doi.org/10.1101/2022.04.07.22273595.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2033147, encodeId=aece203314e6b, content=<a href='/topic/show?id=cebb653925a' target=_blank style='color:#2F92EE;'>#流行病学特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65392, encryptionId=cebb653925a, topicName=流行病学特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Sat Jun 25 22:54:39 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084726, encodeId=fca32084e26bf, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Apr 03 03:54:39 CST 2023, time=2023-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858038, encodeId=ce4c185803825, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Sep 06 10:54:39 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343023, encodeId=969f1343023b1, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391289, encodeId=6310139128915, content=<a href='/topic/show?id=06031149070' target=_blank style='color:#2F92EE;'>#medRxiv#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11490, encryptionId=06031149070, topicName=medRxiv)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411416, encodeId=6332141141642, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611553, encodeId=65c216115533c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2033147, encodeId=aece203314e6b, content=<a href='/topic/show?id=cebb653925a' target=_blank style='color:#2F92EE;'>#流行病学特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65392, encryptionId=cebb653925a, topicName=流行病学特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Sat Jun 25 22:54:39 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084726, encodeId=fca32084e26bf, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Apr 03 03:54:39 CST 2023, time=2023-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858038, encodeId=ce4c185803825, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Sep 06 10:54:39 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343023, encodeId=969f1343023b1, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391289, encodeId=6310139128915, content=<a href='/topic/show?id=06031149070' target=_blank style='color:#2F92EE;'>#medRxiv#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11490, encryptionId=06031149070, topicName=medRxiv)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411416, encodeId=6332141141642, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611553, encodeId=65c216115533c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=)]
    2023-04-03 xjy02
  3. [GetPortalCommentsPageByObjectIdResponse(id=2033147, encodeId=aece203314e6b, content=<a href='/topic/show?id=cebb653925a' target=_blank style='color:#2F92EE;'>#流行病学特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65392, encryptionId=cebb653925a, topicName=流行病学特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Sat Jun 25 22:54:39 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084726, encodeId=fca32084e26bf, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Apr 03 03:54:39 CST 2023, time=2023-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858038, encodeId=ce4c185803825, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Sep 06 10:54:39 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343023, encodeId=969f1343023b1, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391289, encodeId=6310139128915, content=<a href='/topic/show?id=06031149070' target=_blank style='color:#2F92EE;'>#medRxiv#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11490, encryptionId=06031149070, topicName=medRxiv)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411416, encodeId=6332141141642, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611553, encodeId=65c216115533c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2033147, encodeId=aece203314e6b, content=<a href='/topic/show?id=cebb653925a' target=_blank style='color:#2F92EE;'>#流行病学特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65392, encryptionId=cebb653925a, topicName=流行病学特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Sat Jun 25 22:54:39 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084726, encodeId=fca32084e26bf, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Apr 03 03:54:39 CST 2023, time=2023-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858038, encodeId=ce4c185803825, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Sep 06 10:54:39 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343023, encodeId=969f1343023b1, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391289, encodeId=6310139128915, content=<a href='/topic/show?id=06031149070' target=_blank style='color:#2F92EE;'>#medRxiv#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11490, encryptionId=06031149070, topicName=medRxiv)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411416, encodeId=6332141141642, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611553, encodeId=65c216115533c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2033147, encodeId=aece203314e6b, content=<a href='/topic/show?id=cebb653925a' target=_blank style='color:#2F92EE;'>#流行病学特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65392, encryptionId=cebb653925a, topicName=流行病学特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Sat Jun 25 22:54:39 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084726, encodeId=fca32084e26bf, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Apr 03 03:54:39 CST 2023, time=2023-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858038, encodeId=ce4c185803825, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Sep 06 10:54:39 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343023, encodeId=969f1343023b1, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391289, encodeId=6310139128915, content=<a href='/topic/show?id=06031149070' target=_blank style='color:#2F92EE;'>#medRxiv#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11490, encryptionId=06031149070, topicName=medRxiv)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411416, encodeId=6332141141642, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611553, encodeId=65c216115533c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2033147, encodeId=aece203314e6b, content=<a href='/topic/show?id=cebb653925a' target=_blank style='color:#2F92EE;'>#流行病学特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65392, encryptionId=cebb653925a, topicName=流行病学特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Sat Jun 25 22:54:39 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084726, encodeId=fca32084e26bf, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Apr 03 03:54:39 CST 2023, time=2023-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858038, encodeId=ce4c185803825, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Sep 06 10:54:39 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343023, encodeId=969f1343023b1, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391289, encodeId=6310139128915, content=<a href='/topic/show?id=06031149070' target=_blank style='color:#2F92EE;'>#medRxiv#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11490, encryptionId=06031149070, topicName=medRxiv)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411416, encodeId=6332141141642, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611553, encodeId=65c216115533c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=)]
    2022-04-23 xugumin
  7. [GetPortalCommentsPageByObjectIdResponse(id=2033147, encodeId=aece203314e6b, content=<a href='/topic/show?id=cebb653925a' target=_blank style='color:#2F92EE;'>#流行病学特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65392, encryptionId=cebb653925a, topicName=流行病学特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Sat Jun 25 22:54:39 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084726, encodeId=fca32084e26bf, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Apr 03 03:54:39 CST 2023, time=2023-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858038, encodeId=ce4c185803825, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Sep 06 10:54:39 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343023, encodeId=969f1343023b1, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391289, encodeId=6310139128915, content=<a href='/topic/show?id=06031149070' target=_blank style='color:#2F92EE;'>#medRxiv#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11490, encryptionId=06031149070, topicName=medRxiv)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2500074, createdName=124987e8m07暂无昵称, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411416, encodeId=6332141141642, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611553, encodeId=65c216115533c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 23 06:54:39 CST 2022, time=2022-04-23, status=1, ipAttribution=)]

相关资讯

中国香港昨日新增613例,连续多日低于1000例(2022.04.18)

香港特区政府卫生署卫生防护中心18日公布,截至当日零时,香港新增613例确诊的新冠肺炎病例,其中经核酸检测确诊病例316例。香港连续4天录得3位数的确诊病例。4月17日,新冠病毒快速抗原测试阳性结果人

中国香港昨日新增794例,连续两日低于1000例(2022.04.16)

香港第五波疫情近期持续呈下降趋势,新增确诊连续两天在1000例以下,特区政府卫生署卫生防护中心4月16日下午通报,截至当日零时,新增794例,其中449例核酸检测确诊病例,新增345例快速抗原测试阳性

中国香港昨日新增946例,新增回落至3位数以内,实现林郑月娥提出目标(2022.04.15)

香港特区政府卫生署卫生防护中心15日公布,截至当日零时,香港新增946例确诊的新冠肺炎病例,其中经核酸检测确诊病例471例。香港单日新增病例自2月11日起连续63天过千后,回落至三位数。

中国香港昨日新增1272例,连续4天单日新增病例低于2000宗(2022.04.13)

香港特区政府卫生署卫生防护中心13日公布,截至当日零时,香港新增1272例新冠肺炎确诊病例,其中经核酸检测确诊病例734例。4月12日,新冠病毒快速抗原测试阳性结果人士申报系统接获538例呈报病例。据

香港昨日新增1433例,连续3天单日新增病例低于2000宗

香港特区政府卫生署卫生防护中心4月12日公布,截至当日零时,香港新增1433例确诊的新冠肺炎病例,其中经核酸检测确诊病例735例。

中国香港昨日新增1043例,疫情快速消退(2022.04.14)

香港特区政府卫生署卫生防护中心14日公布,截至当日零时,香港新增1043例确诊的新冠肺炎病例,其中经核酸检测确诊病例579例。